| Company/Division name | Calidi Biotherapeutics, Inc. |
| Parent company | Calidi Biotherapeutics, Inc. |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2020 |
| Country(ies) from which reshored: | Korea, Republic of |
| City reshored to: | San Diego |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | cell-based immunotherapies for cancer |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Other, expansion |
